Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BMRA vs BNBX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BMRA Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–2 Matrix Metrics)

BMRA Overall Winner 6-Pillar Tally: BMRA 2 – 2 BNBX (2 Tie) Matrix Metrics: BMRA 5 – 2 BNBX

As of Nov 16, 2026, Biomerica Inc (BMRA) is the stronger overall head-to-head candidate over BNB Plus Corp. (BNBX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas BNBX carries 37.7/100 (SELL) at $0.16 (N/M Forward P/E, -636.4% operating margin).

  • Growth vs. Quality Trade-Off: BMRA earns the overall head-to-head edge with a stronger Unified Composite Score (44.5/100 HOLD vs. BNBX 37.7/100 SELL) and 0.67β · 62% Vol risk profile, whereas BNBX leads top-line expansion (+34.3% YoY revenue growth, 1.27x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile BNBX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMRA vs BNBX
BMRA NASDAQ Head-to-Head Winner
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.36
+0.0% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96
BNBX US Equity
BNB Plus Corp.
Finance Services
$0.16
-56.75% 1D
Market Cap $2.7M
TTM Revenue $2.1M
Forward P/E N/M
Beta / 30D Vol 1.68β · 227% Vol
Unified Composite Score
37.7 / 100 SELL
Tech 40.0 Fund 46.0 Flow 50.0 Mom 48.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.6%), weak momentum, RSI 22
RSI-14: 21.9 · SMA20: $0.39 · SMA50: $0.44

6-Pillar Scorecard Institutional Category Breakdown (BMRA 2 – 2 BNBX)

Columns: Metric · BMRA · BNBX
1. Valuation Multiples BNBX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M 1.27x
EV / Revenue 1.1x 0.8x
2. Growth & Scale BNBX
Revenue Growth (YoY) -8.3% +34.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $4.3M $2.1M
Market Cap $6.0M $2.7M
3. Profitability & Quality BMRA
Gross Margin 0.9% 46.8%
Operating Margin -125.2% -636.4%
Net Profit Margin -115.5% 0.0%
Return on Equity (ROE) -113.8% -306.8%
4. Balance Sheet & Cash Flow BMRA
Cash Generation (TTM) -$3.2M -$32M EBITDA
Cash Flow Margin -73.5% N/A
Net Cash / Leverage $1.1M Net Cash -$949,091 Net Debt (0.00x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Asset Management Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMRA (5) vs BNBX (2)
Institutional Metric BMRA BNBX Criterion Row Edge
Market Capitalization
Scale
$6.0M $2.7M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-8.3% +34.3% Higher Growth BNBX
Operating Margin (TTM)
Profitability
-125.2% -636.4% Higher Margin BMRA
Net Profit Margin
Profitability
-115.5% 0.0% Higher Margin BNBX
Return on Equity (ROE)
Capital Efficiency
-113.8% -306.8% Higher ROE BMRA
52-Week Range Position
Momentum
5% ($1–$3) 0% ($0–$7) Stronger Trend BMRA
Beta / 30D Volatility
Risk Regime
0.67β · 62% Vol 1.68β · 227% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 37.7 / 100 (SELL) Higher Composite BMRA
Trailing 12M Revenue (USD)
Operating Scale
$4.3M $2.1M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.9% 46.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.1x EV/Rev 1.27x PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.2M ($1.1M Net Cash) -$32M EBITDA (-$949,091 Net Debt (0.00x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BMRA +51.06 pp
BMRA: -16.34% · BNBX: -67.4%
3M Horizon BMRA +51.24 pp
BMRA: -20.66% · BNBX: -71.9%
6M Horizon BMRA +48.62 pp
BMRA: -41.32% · BNBX: -89.94%
1Y Horizon BMRA +62.36 pp
BMRA: -32.4% · BNBX: -94.76%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BMRA Revenue BNBX Revenue BMRA Op. Margin BNBX Op. Margin Margin Leader
FY2019 $10M $10M -46.4% -169.3% BMRA
FY2020 $10M $0M -41.0% -649.0% BMRA
FY2021 $10M $10M -104.2% -147.9% BMRA
FY2022 $20M $20M -24.0% -76.9% BMRA
FY2023 $10M $10M -135.3% -81.9% BNBX
FY2024 $10M $0M -117.6% -646.7% BMRA
FY2025 $10M $0M -96.7% -750.9% BMRA
FY2026 $0M N/A -119.5% N/A BMRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BNBX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BNBX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BNBX Moat Profile Cyclical / Execution-Driven Positioning
Asset Management Operator
Competes within the Asset Management value chain with $2.7M market capitalization and -636.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BMRA vs BNBX Key Questions & Quantitative Answers

As of Nov 16, 2026, Biomerica Inc (BMRA) is the stronger overall head-to-head candidate over BNB Plus Corp. (BNBX) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas BNBX carries 37.7/100 (SELL) at $0.16 (N/M Forward P/E, -636.4% operating margin). Growth vs. Quality Trade-Off: BMRA earns the overall head-to-head edge with a stronger Unified Composite Score (44.5/100 HOLD vs. BNBX 37.7/100 SELL) and 0.67β · 62% Vol risk profile, whereas BNBX leads top-line expansion (+34.3% YoY revenue growth, 1.27x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile BNBX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BNBX leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with BNBX at +34.3% YoY revenue growth and +0.0% YoY earnings growth on $2.1M TTM revenue (46.8% gross margin, -636.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), BMRA cumulative revenue shifted +0.0% while BNBX shifted +0.0%. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BNBX.

BNBX screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas BNBX trades at N/M Forward P/E, N/M Trailing P/E, 1.27x PEG, and 0.8x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus BNBX (-306.8% ROE) capital efficiency.

In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, BNBX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.68β · 227% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.